Advertisement

Management of Shunt Related Infections

Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 719)

Abstract

Cerebrospinal fluid (CSF) shunts are used to reduce the increased pressure inside the brain’s ventricles and divert that fluid to other body sites for absorption. The proximal portion of the shunt is usually placed in one of the cerebral ventricles, or sometimes inside a brain cyst, subarachnoidal, or lumbar spaces and the distal portion can be internalized or externalized. Internalized devices are usually placed in the peritoneal cavity (Ventriculo-peritoneal ‘VP’ shunt) or less likely in the heart atrium (Ventriculo-atrial ‘VA’ shunt) and rarely in the pleural cavity (Ventriculo-pleural shunt). Sometimes shunts can be externalized temporarily for CSF therapeutic diversion or intracranial pressure monitoring (External Ventricular Drain ‘EVD’) and sometimes they are externalized for administration of cancer chemotherapy into a brain tumor or administration of antibiotics (Ommaya reservoir).

Keywords

Shunt Infection Ommaya Reservoir Shunt Catheter Shunt Device Double Glove 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Borgbjerg BM, Gjerris F, Albeck MJ, Borgesen SE. Risk of infection after cerebrospinal fluid shunt: an analysis of 884 first-time shunts. Acta Neurochir (Wien) 1995;36(1–2):1–7.CrossRefGoogle Scholar
  2. 2.
    Caldarelli M, Rocco C, Marca FL. Shunt complications in the first postoperative year in children with myelomeningocele. Childs Nerv Syst 1996;12(12):748–54.PubMedCrossRefGoogle Scholar
  3. 3.
    George R, Leibrock L, Epstein M Long-term analysis of cerebrospinal fluid shunt infections. A 25 year experience. J Neurosurg. 1979;51(6):804–11.PubMedCrossRefGoogle Scholar
  4. 4.
    McGirt MJ, Leveque J-C, Wellons III JC, Villavicencio AT, Hopkins JS, Fuchs HE, et al. Cerebrospinal Fluid Shunt Survival and Etiology of Failures: A Seven-Year Institutional Experience. Pediatric Neurosurgery 2002;36(5):248–55.PubMedCrossRefGoogle Scholar
  5. 5.
    Cochrane DD, Kestle J. Ventricular shunting for hydrocephalus in children: patients, procedures, surgeons and institutions in English Canada, 1989–2001. Eur J Pediatr Surg 2002;12(S11):S6–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Simon TD, Hall M, Riva-Cambrin J, Albert JE, Jeffries HE, Lafleur B, Dean JM, Kestle JR ; Hydrocephalus Clinical Research Network. Infection rates following initial cerebrospinal fluid shunt placement across pediatric hospitals in the United States. Neurosurg Pediatr 2009;4(2):156–65.CrossRefGoogle Scholar
  7. 7.
    Kulkarni AV, Drake JM, Lamberti-Pasculli M. Cerebrospinal fluid shunt infection: a prospective study of risk factors. J Neurosurg. 2001;94(2):195–201.PubMedCrossRefGoogle Scholar
  8. 8.
    Langley JM, Gravel D, Moore D, Matlow A, Embree J, MacKinnon-Cameron D, Conly D. Study of Cerebrospinal Fluid Shunt- Associated Infections in the First Year Following Placement, by the Canadian Nosocomial Infection Surveillance Program. infection control and hospital epidemiology 2009;30(3):285–88.PubMedCrossRefGoogle Scholar
  9. 9.
    Clemmensen D, Rasmussen MM, Mosdal C. A retrospective study of infections after primary VP shunt placement in the newborn with myelomeningocele without prophylactic antibiotics. Childs Nerv Syst. 2010;26(11): 1517–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Sarguna P, Lakshmi V. Ventriculoperitoneal shunt infections. Indian Journal of Medical Microbiology 2006;24(1):52–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Brook I. Meningitis and shunt infection caused by anaerobic bacteria in children. Pediatr Neurol. 2002;26(2): 99–105.PubMedCrossRefGoogle Scholar
  12. 12.
    Montero A, Romero J, Vargas JA, Regueiro CA, Sánchez-Aloz G, De Prados F, De la Torre A, and Aragon G. Candida Infection of Cerebrospinal Fluid Shunt Devices: Report of Two Cases and Review of the Literature. Acta Neurochir (Wien) 2000;142(1):67–74.CrossRefGoogle Scholar
  13. 13.
    Benca J, Ondrusova A, Huttova M >, Rudinsky B, Kisac P, Bauer F. Neuroinfections due to Enterococcus faecalis in children. Neuro Endocrinol Lett. 2007;28(S2):S32–3.Google Scholar
  14. 14.
    Sanchez-Portocarrero J, Martin-Rabadan P, Saldana CJ, Perez- Cecilia E. Candida cerebrospinal Fluid shunt infections. Report of two new cases and review of the literature. Diagn Microbiol Infect Dis 1994;20(1): 33–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Turgut M, Alabaz D, Erbey F, Kocabas E, Erman T, Alhan E, Aksaray N. Cerebrospinal fluid shunt infections in children.. Pediatr Neurosurg. 2005; 41(3):131–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Montano N, Sturiale C, Paternoster G, Lauretti L, Fernandez E, Pallini R. Massive ascites as unique sign of shunt infection by Propionibacterium acnes. Br J Neurosurg. 2010;24(2):221–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Fux CA, Quigley M, Worel AM, Post C, Zimmerli S, Ehrlich G, Veeh RH.. Biofilm-related infections of cerebrospinal fluid shunts. Clin Microbiol Infect. 2006;12(4):331–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Braxton EE Jr, Ehrlich GD, Hall-Stoodley L, Stoodley P, Veeh R, Fux C, Hu FZ, Quigley M, Post JC. Role of biofilms in neurosurgical device-related infections. Neurosurg Rev. 2005;28(4):249–55.PubMedCrossRefGoogle Scholar
  19. 19.
    Kestle JRW, Garton HJL, Whitehead WE, Drake JM, Kulkarni AV, Cochrane DD, Muszynski C, and Walker ML.. Management of shunt infections: a multicenter pilot study. J Neurosurgery 2006;105(S3):S177-81.Google Scholar
  20. 20.
    Schreffler RT, Schreffler A, Wittler RR. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J 2002;21(7):632–6.PubMedCrossRefGoogle Scholar
  21. 21.
    James HE, Walsh JW, Wilson HD, Connor JD, Bean JR, Tibbs PA. The management of cerebrospinal fluid shunt infections: a clinical experience. Acta Neurochir (Wien) 1981;59(3–4):157–66.CrossRefGoogle Scholar
  22. 22.
    Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39(9):1267–84.PubMedCrossRefGoogle Scholar
  23. 23.
    Gombert ME, Landesman SH, Corrado ML, Stein SC, Melvin ET, Cummings M. Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts: report of three cases. J Neurosurg. 1981;55(4):633–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Maranich AM, Rajnik M. Successful treatment of vancomycin-resistant enterococcal ventriculitis in a pediatric patient with linezolid. Mil Med. 2008;173(9):927–9.PubMedGoogle Scholar
  25. 25.
    Castro P, Soriano A, Escrich C, Villalba G, Sarasa M, Mensa J. Linezolid treatment of ventriculoperitoneal shunt infection without implant removal. Eur J Clin Microbiol Infect Dis. 2005;24(9):603–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother. 2007;41(2):296–308.PubMedCrossRefGoogle Scholar
  27. 27.
    Yilmaz A, Dalgic N, Müslüman M, Sancar M, Colak I, Aydin Y. Linezolid treatment of shunt-related cerebrospinal fluid infections in children. J Neurosurg Pediatr. 2010;5(5):443–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Wen DY, Bottini AJ, Hall WA, Haines SJ. The intraventricular use of antibiotics. Neurosurg Clin North Am 1992;3(2):343–54.Google Scholar
  29. 29.
    Arnell K, Enblad P, Wester T, Sjölin J. Treatment of cerebrospinal fluid shunt infections in children using systemic and intraventricular antibiotic therapy in combination with externalization of the ventricular catheter: efficacy in 34 consecutively treated infections. J Neurosurg. 2007;107(S 3): S 213–9.Google Scholar
  30. 30.
    Chiou CC, Wong TT, Lin HH, Hwang B, Tang RB, Wu KG, Lee BH. Fungal infection of ventriculoperitoneal shunts in children. Clin Infect Dis 1994;19(6):1049–53.PubMedCrossRefGoogle Scholar
  31. 31.
    Shapiro S, Javed T, Mealey J,. Candida albicans shunt infection. Pediatr Neurosci 1989; 15:125–30.PubMedCrossRefGoogle Scholar
  32. 32.
    Pappas PG, Kauffman C, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.PubMedCrossRefGoogle Scholar
  33. 33.
    James HE, Bradley JS. Management of complicated shunt infections: a clinical report. J Neurosurg Pediatr. 2008;1(3):223–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Choksey MS, Malik IA. Zero tolerance to shunt infections: can it be achieved? J Neurol Neurosurg Psychiatry 2004;75(1):87–91.PubMedGoogle Scholar
  35. 35.
    Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts: a systematic review. J Neurosurg Pediatr. 2008;1(1):48–56.PubMedCrossRefGoogle Scholar
  36. 36.
    Nejat F, Tajik P, El Khashab M, Kazmi SS, Khotaei GT, Salahesh S. A randomized trial of ceftriaxone versus trimethoprim-sulfamethoxazole to prevent ventriculoperitoneal shunt infection. J Microbiol Immunol Infect. 2008;41(2):112–7.PubMedGoogle Scholar
  37. 37.
    Tacconelli E, Cataldo MA, Albanese A, Tumbarello M, Arduini E, Spanu T, et al. Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus. J. Hosp Infect 2008;69(4):337–44.PubMedCrossRefGoogle Scholar
  38. 38.
    Wong GK, Poon WS, Lyon D, Wai S. Cefepime vs. Ampicillin/Sulbactam and Aztreonam as antibiotic prophylaxis in neurosurgical patients with external ventricular drain: result of a prospective randomized controlled clinical trial. J Clin Pharm Ther. 2006;31(3):231–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Pattavilakom A, Xenos C, Bradfield O, Danks RA. Reduction in shunt infection using antibiotic impregnated CSF shunt catheters: an Australian prospective study. J Clin Neurosci. 2007;14(6):526–31.PubMedCrossRefGoogle Scholar
  40. 40.
    Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson J, Robertson C, et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. J Neurosurg. 2003;98(4):725–30.PubMedCrossRefGoogle Scholar
  41. 41.
    Muttaiyah S, Ritchie S, John S, Mee E, Roberts S. Efficacy of antibiotic-impregnated external ventricular drain catheters. J Clin Neurosci. 2010;17(3):296–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Richards HK, Seeley HM, Pickard JD. Efficacy of antibiotic-impregnated shunt catheters in reducing shunt infection: data from the United Kingdom Shunt Registry. J Neurosurg Pediatr. 2009;4(4):389–93.PubMedCrossRefGoogle Scholar
  43. 43.
    Gutiérrez-González R, Boto GR, Fernández-Pérez C, Del Prado N. Protective effect of rifampicin and clindamycin impregnated devices against Staphylococcus spp. infection after cerebrospinal fluid diversion procedures. BMC Neurol. 2010;10:93.PubMedCrossRefGoogle Scholar
  44. 44.
    Sciubba DM, Lin LM, Woodworth GF, McGirt MJ, Carson B, Jallo GI. Factors contributing to the medical costs of cerebrospinal fluid shunt infection treatment in pediatric patients with standard shunt components compared with those in patients with antibiotic impregnated components. Neurosurg Focus. 2007;22(4):E9.PubMedCrossRefGoogle Scholar
  45. 45.
    Parker SL, Attenello FJ, Sciubba DM, Garces-Ambrossi GL, Ahn E, Weingart J, et al. Comparison of shunt infection incidence in high-risk subgroups receiving antibiotic-impregnated versus standard shunts. Childs Nerv Syst. 2009;25(1):77–83.PubMedCrossRefGoogle Scholar
  46. 46.
    Govender ST, Nathoo N, van Dellen JR. Evaluation of an antibiotic-impregnated shunt system for the treatment of hydrocephalus. J Neurosurg Pediatr. 2003;99(5):831–9.Google Scholar
  47. 47.
    Albanese A, De Bonis P, Sabatino G, Capone G, Marchese E, Vignati A, et al. Antibiotic-impregnated ventriculo-peritoneal shunts in patients at high risk of infection. Acta Neurochir (Wien) 2009;151(10):1259–63.CrossRefGoogle Scholar
  48. 48.
    Wong GK, Poon WS, Ng SC, Ip M. The impact of ventricular catheter impregnated with antimicrobial agents on infections in patients with ventricular catheter: interim report.. Acta Neurochir Suppl. 2008;102: 53–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Hayhurst C, Williams D, Kandasamy J, O’Brien DF, Mallucci CL. The impact of antibiotic-impregnated catheters on shunt infection in children and neonates. Childs Nerv Syst. 2008;24(5):557–62.PubMedCrossRefGoogle Scholar
  50. 50.
    Stevens EA, Palavecino E, Sherertz RJ, Shihabi Z, Couture DE. Effects of antibiotic-impregnated external ­ventricular drains on bacterial culture results: an in vitro analysis. J. Neurosurg. 2010;113(1):86–92.PubMedCrossRefGoogle Scholar
  51. 51.
    Gruber TJ, Reimer S, Rozelle C. Pediatric Neurosurgical Practice Patterns Designated to prevent Cerebrospinal Fluid shunt infection. Pediatric Neurosurgery 2009;45(6):456–60.PubMedCrossRefGoogle Scholar
  52. 52.
    Rehman AU, Rehman TU, Bashir HH, Gupta V. A simple method to reduce infection of ventriculoperitoneal shunts. J Neurosurg Pediatr. 2010;5(6):569–72.PubMedCrossRefGoogle Scholar
  53. 53.
    Dasic D, Hanna SJ, Bojanic S, Kerr RS. External ventricular drain infection: the effect of a strict protocol on infection rates and a review of the literature. Br J Neurosurg. 2006;20(5):296–300.PubMedCrossRefGoogle Scholar
  54. 54.
    Rozzelle CJ, Leonardo J, Li V. Antimicrobial suture wound closure for cerebrospinal fluid shunt surgery: a prospective, double-blinded, randomized controlled trial. J Neurosurg Pediatr. 2008;2(2):111–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Stone J, Gruber TJ, Rozzelle CJ. Healthcare savings associated with reduced infection rates using antimicrobial suture wound closure for cerebrospinal fluid shunt procedures. Pediatr Neurosurg. 2010;46(1):19–24.PubMedCrossRefGoogle Scholar
  56. 56.
    Shaikh ZH, Peloquin CA, Ericsson CD Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis. 2001;33(5):375–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Williamson JC, Glazier SS, Peacock JEJ. Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin Clin Neurol Neurosurg 2002;104(1):54–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Arnell K, Cesarini K, Lagerqvist-Widh A, Wester T, Sjölin J. Cerebrospinal fluid shunt infections in children over a 13-year period: anaerobic cultures and comparison of clinical signs of infection with Propionibacterium acnes and with other bacteria. J Neurosurg Pediatr. 2008;1(5):366–72.PubMedCrossRefGoogle Scholar
  59. 59.
    Bayston R, Nuradeen B, Ashraf W, Freeman BJ. Antibiotics for the eradication of Propionibacterium acnes biofilms in surgical infection. J Antimicrob Chemother. 2007;60(6):1298–301.PubMedCrossRefGoogle Scholar
  60. 60.
    Murphy K, Bradley J, James HE. The treatment of Candida albicans shunt infections. Childs Nerv Syst. 2000;16(1):4–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Infectious and Immunological Diseases, Department of PediatricsBC Children’s HospitalVancouverCanada

Personalised recommendations